Does Cigna Cover Forteo?

What Is Forteo and Why Does Coverage Matter?

Forteo (teriparatide) is a recombinant fragment of human parathyroid hormone used to build new bone in patients with severe osteoporosis. Coverage matters because the drug's list price runs roughly $3,200 per 28-day pen, and most patients require 24 months of continuous treatment. Without insurance support, the full treatment course can exceed $76,000.

Teriparatide works differently from antiresorptive agents like bisphosphonates or denosumab. Rather than simply slowing bone breakdown, it actively stimulates osteoblasts to deposit new bone matrix. The key trial supporting its approval (Neer et al., 2001, N=1,637) showed that teriparatide 20 mcg/day reduced the relative risk of new vertebral fractures by 65% compared to placebo at a median of 21 months, a finding that secured its FDA approval in 2002 [1]. That evidence base is exactly what Cigna's medical policy reviewers examine when evaluating prior authorization requests.

Because teriparatide is a self-injectable specialty biologic dispensed through specialty pharmacies, Cigna routes it through the pharmacy benefit (not the medical benefit) on most plans, placing it in a high-cost specialty tier. That tier placement, combined with mandatory prior authorization, is the central obstacle most patients face.

How Cigna Classifies Forteo on Its Formulary

Cigna places Forteo in Specialty Tier 4 or Tier 5 on most commercial formularies, which typically means a coinsurance of 25-33% rather than a flat copay. Tier placement is not universal. It shifts by plan year, employer group contract, and whether the plan uses Cigna's standard formulary or a custom employer formulary.

On plans that have added the FDA-approved teriparatide biosimilar (marketed as Brixelle by Alvogen, approved by the FDA in June 2023 [2]), the biosimilar may sit one tier lower than the brand, meaning Brixelle could carry a lower coinsurance rate. Cigna's pharmacy team typically follows the same clinical criteria for both the brand and the biosimilar.

Checking your specific tier requires logging into myCigna.com and running a drug search under your active plan year, or calling the pharmacy benefits number on the back of your insurance card. Formulary documents are published annually but can change mid-year for specialty drugs, so a search done six months ago may not reflect today's cost-share.

The key practical point: even if Forteo is listed on the formulary, that listing does not guarantee automatic dispensing. It means the drug is eligible for coverage once prior authorization criteria are satisfied.

Prior Authorization Criteria Cigna Typically Requires

Getting prior authorization approved for Forteo through Cigna requires satisfying a defined set of clinical criteria. The exact criteria vary by plan, but Cigna's published osteoporosis specialty drug policies converge on the following core requirements [3]:

Diagnosis confirmation. The prescriber must document a diagnosis of osteoporosis based on a dual-energy X-ray absorptiometry (DXA) scan showing a T-score of -2.5 or lower at the spine or hip, OR documented fragility fracture (hip or vertebral) regardless of T-score.

Step therapy completion. Most Cigna plans require at least six to twelve months of therapy with an oral bisphosphonate (alendronate 70 mg weekly is the most common requirement) before Forteo will be authorized, unless the prescriber documents a contraindication, intolerance, or clinical failure. Contraindications that bypass step therapy include esophageal disorders, documented GI intolerance, and inability to remain upright for 30 minutes post-dose.

Appropriate prescriber. The prescribing clinician should be, or should have consulted with, an endocrinologist, rheumatologist, or physician with documented osteoporosis management experience.

Duration limit. Cigna follows the FDA black-box warning and the American Association of Clinical Endocrinologists (AACE) 2020 Clinical Practice Guidelines, which cap teriparatide use at 24 months lifetime [4]. The prior authorization is typically issued for six months initially and renewed every six months up to the 24-month ceiling.

Quantity limits. One 2.4 mL prefilled delivery device (delivering 28 daily 20-mcg doses) per 28-day supply.

The AACE 2020 Osteoporosis Guidelines state: "Anabolic therapy with teriparatide or abaloparatide should be reserved for patients at very high or imminent fracture risk, especially those with severe or multiple vertebral fractures, and should be followed by antiresorptive therapy to maintain gains." [4] That statement frequently appears in Cigna medical necessity reviews as the clinical standard against which requests are judged.

Step Therapy: The Bisphosphonate Hurdle

Step therapy is the most common reason initial Forteo authorization requests are denied. Cigna requires documented evidence that the patient has tried and failed, or has a documented contraindication to, at least one bisphosphonate before Forteo will be approved.

Alendronate (Fosamax) 70 mg weekly is the most commonly required first-step agent because it is generic, inexpensive, and supported by a large fracture-reduction evidence base. The Fracture Intervention Trial (FIT, N=2,027) showed alendronate reduced hip fracture risk by 51% and vertebral fracture risk by 47% over three years in postmenopausal women with existing vertebral fractures [5]. That established efficacy is exactly why payers position it as a first-line requirement.

For patients who genuinely cannot tolerate oral bisphosphonates (esophagitis, Barrett esophagus, documented upper GI bleeding), the prescriber's documentation of intolerance with supporting clinical notes typically satisfies the step-therapy requirement and unlocks Forteo authorization without waiting months for a failed trial.

For patients who tolerated a bisphosphonate but continued to fracture, Cigna generally accepts a new fracture occurring during bisphosphonate therapy as documented failure. A vertebral fracture documented on imaging while a patient was adherent to alendronate for 12 months is strong evidence of clinical failure and should be included in the prior authorization submission.

Medicare Advantage and Part D Coverage of Forteo Through Cigna

Patients enrolled in Cigna Medicare Advantage plans or Cigna-administered Part D plans face a somewhat different coverage structure. Medicare Part D places Forteo in Tier 5 (specialty tier) on most plan formularies, with a coinsurance of approximately 25-33% during the initial coverage phase.

Under the Inflation Reduction Act provisions phased in starting in 2025, Medicare Part D enrollees have a $2,000 annual out-of-pocket cap on covered Part D drugs [6]. For a 24-month Forteo course, this cap can represent significant savings compared to pre-IRA cost exposure.

Prior authorization requirements for Medicare Advantage plans mirror commercial plan criteria, but the appeals process is governed by Medicare rules rather than state insurance law. Cigna Medicare Advantage enrollees have the right to request an expedited redetermination within 72 hours if the treating physician certifies that the standard 7-day appeal timeline would seriously jeopardize the enrollee's health or ability to regain maximum function.

The CMS Medicare Prescription Drug Benefit Manual, Chapter 18, Section 60.1 states that plan sponsors must establish a standardized exception and appeals process that allows enrollees to request exceptions to formulary tier placement or step-therapy requirements when the standard covered drug is contraindicated or would be expected to be less effective or cause an adverse reaction [6].

What Forteo Actually Costs With Cigna Coverage

Even with Cigna coverage, specialty-tier coinsurance can leave patients with substantial out-of-pocket costs. A rough breakdown helps clarify realistic cost exposure:

With a 25% coinsurance and a $3,200 monthly list price, the patient's monthly share before deductible credits is approximately $800. Over 24 months, that adds up to roughly $19,200 before any deductible offset or manufacturer assistance.

Once an annual deductible is satisfied, the math shifts. On plans with a $3,000 deductible, the first month or two of Forteo fills may go entirely to the deductible, after which coinsurance applies.

Eli Lilly patient-assistance program. The Lilly Cares Foundation Patient Assistance Program provides Forteo at no cost to uninsured patients meeting income eligibility criteria. For commercially insured patients, the Lilly Forteo Savings Card can reduce monthly cost-share to as low as $0 per month, with a cap on the annual benefit. Cigna plans that are ACA-compliant commercial plans qualify; however, Medicare and Medicaid beneficiaries cannot use manufacturer copay cards due to federal anti-kickback rules [7].

Specialty pharmacy negotiation. Cigna's specialty pharmacy network, which includes Accredo (a Cigna subsidiary), may offer slightly lower dispensing fees than out-of-network specialty pharmacies. Staying in-network for specialty drug fills can reduce overall cost by 5-15% depending on plan design.

How to Submit a Prior Authorization Request for Forteo Through Cigna

The prescribing physician (or the patient's care team) initiates the PA request. The process typically works as follows:

First, the provider submits a PA request through Cigna's provider portal (CignaforHCP.com) or via fax using Cigna's specialty drug prior authorization form. The form requests the patient's diagnosis (ICD-10 code M81.0 for age-related osteoporosis or M80.08 for other osteoporosis with current pathological fracture), DXA T-score, fracture history, prior bisphosphonate therapy documentation, and prescriber information.

Second, Cigna's pharmacy clinical review team (typically a pharmacy technician and then a clinical pharmacist) reviews the submission within 72 hours for standard requests and within 24 hours for urgent requests.

Third, if the initial review identifies missing documentation, a peer-to-peer review call between Cigna's reviewing pharmacist or physician and the prescribing clinician can be requested. This call is the single highest-yield step when an initial denial seems likely. Getting the prescriber on the phone to explain clinical context resolves a significant share of denials before they are formally issued.

Fourth, if a denial is issued, the prescriber or patient can file a first-level internal appeal within 30 to 180 days (the window varies by plan). For Medicare Advantage, the appeal window is 60 days from the notice of denial.

Appealing a Cigna Denial for Forteo

Denials are not final decisions. Roughly 40-60% of specialty drug prior authorization denials are overturned on first internal appeal when supported by complete clinical documentation.

A strong Forteo appeal package includes:

A letter of medical necessity from the treating physician that explicitly cites the patient's T-score, documented fractures, prior treatment history, and references current clinical guidelines. Quoting directly from the AACE 2020 Osteoporosis Guidelines [4] or the American College of Rheumatology 2022 Osteoporosis Guideline Update [8] adds credibility and shows the request aligns with peer-reviewed standards.

DXA scan results from the most recent test, ideally within the last 24 months.

Documentation of prior bisphosphonate therapy, including start date, dose, duration, and reason for discontinuation or clinical failure.

Any relevant fracture imaging (plain X-ray, CT, or MRI showing vertebral compression fracture or hip fracture).

If the first-level internal appeal fails, patients have the right to request an independent external review through a state-certified independent review organization (IRO). For Medicare Advantage denials, the escalation path goes to a Qualified Independent Contractor (QIC) review, then to an Administrative Law Judge (ALJ) hearing if the amount in controversy exceeds $180 (2024 threshold).

The Patient Advocate Foundation operates a free case management service for patients navigating specialty drug denials and can assist with preparing appeal documentation at no cost to the patient [9].

Alternatives If Forteo Remains Unaffordable or Uncovered

If Forteo coverage cannot be secured through Cigna, several clinical alternatives address severe osteoporosis with comparable or complementary mechanisms:

Abaloparatide (Tymlos). Abaloparatide is a parathyroid hormone-related protein (PTHrP) analog with a similar anabolic mechanism. The ACTIVE trial (N=2,463) showed abaloparatide reduced new vertebral fracture risk by 86% compared to placebo over 18 months [10]. Some Cigna formularies prefer abaloparatide over teriparatide based on negotiated pricing, meaning Tymlos may face fewer coverage hurdles than Forteo on specific plan designs.

Romosozumab (Evenity). Romosozumab is a sclerostin inhibitor with a dual mechanism (bone formation increase plus bone resorption decrease). The ARCH trial (N=4,093) showed romosozumab followed by alendronate reduced hip fracture risk by 38% compared to alendronate alone over 24 months [11]. Romosozumab carries a black-box warning for cardiovascular risk and requires monthly subcutaneous injections administered by a healthcare provider, which means it routes through the medical benefit rather than the pharmacy benefit on most Cigna plans.

Denosumab (Prolia). Denosumab 60 mg subcutaneously every 6 months is an antiresorptive RANK-L inhibitor that Cigna typically covers with fewer step-therapy hurdles. The FREEDOM trial (N=7,808) showed denosumab reduced vertebral fracture risk by 68% over 36 months [12]. It does not build new bone to the same degree as anabolic agents, but it represents a meaningful option for patients who cannot access teriparatide.

Clinical Red Flags That Strengthen a Forteo PA Request

Certain clinical scenarios nearly always satisfy Cigna's medical necessity criteria and should be prominently documented in any PA submission.

Multiple vertebral fractures on a single imaging study represent the clearest case for anabolic therapy. The AACE guidelines list "two or more vertebral fractures" as a threshold for considering anabolic therapy as first-line (skipping the bisphosphonate step-therapy requirement) [4].

A T-score below -3.0 with at least one fragility fracture places a patient in the "very high risk" category defined by the AACE risk stratification model, which supports immediate anabolic therapy.

Hip fracture within the past 24 months is treated as a high-urgency indication. Cigna's clinical reviewers typically approve urgent PA requests for post-hip-fracture patients within 24 hours when clinical documentation is complete.

Glucocorticoid-induced osteoporosis (GIOP) in patients taking prednisone 7.5 mg/day or more for three or more months is explicitly recognized as an indication in Forteo's FDA label [13] and may face slightly different step-therapy requirements than primary osteoporosis.